# Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)

> **NCT03541668** · PHASE3 · COMPLETED · sponsor: **Tasly Biopharmaceuticals Co., Ltd.** · enrollment: 674 (actual)

## Conditions studied

- Acute Ischaemic Stroke

## Interventions

- **DRUG:** Recombinant human urokinase
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT03541668
- **Lead sponsor:** Tasly Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-18
- **Primary completion:** 2020-04-14
- **Final completion:** 2020-05-24
- **Target enrollment:** 674 (ACTUAL)
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03541668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03541668, "Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03541668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*